Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017

Cited by 1,207 works. doi:10.1016/s1470-2045(17)30608-3

Authors

References